Gilead is paying $1.68 billion for a T-cell engager company via a front-loaded deal that could also give new meaning to its aimless partner Galapagos.
- Home |
- Gilead’s $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos
Gilead’s $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos
- March 24, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
